The list price for Aimovig (erenumab-aooe) in 2023 can vary depending on factors such as the specific dosage and the pharmacy where it is dispensed. However, manufacturer coupons and patient assistance programs are often available to help reduce out-of-pocket costs.
What is the typical monthly cost of Aimovig?
For a 140 mg monthly dose, the average retail price is approximately $6,792, though this can fluctuate [1].
How can patients afford Aimovig?
Novartis, the manufacturer of Aimovig, offers the Aimovig Co-Pay Card program. This program can reduce the monthly co-pay for eligible commercially insured patients to as low as $0 for a 12-month period, with a maximum annual savings of $2,900 [2]. For those without commercial insurance or who are uninsured, Novartis also provides a Patient Assistance Program (PAP) that may offer Aimovig at no cost or a reduced cost, depending on income eligibility [3].
When does Aimovig's patent protection expire?
Patent expiry dates are crucial for understanding when generic or biosimilar versions might become available, potentially lowering costs. Information on Aimovig's specific patent expirations is tracked by resources like DrugPatentWatch.com [4].
What are Aimovig's approved indications?
Aimovig is approved by the U.S. Food and Drug Administration (FDA) for the preventive treatment of migraine in adults [5].
How is Aimovig administered?
Aimovig is a self-administered subcutaneous injection [5].
What are the potential side effects of Aimovig?
Common side effects reported in clinical trials include injection site reactions, constipation, and muscle spasms [5]. More serious side effects, though rare, can include serious allergic reactions.
How does Aimovig work to prevent migraines?
Aimovig is a monoclonal antibody that targets the calcitonin gene-related peptide (CGRP) receptor [5]. By blocking CGRP, a molecule implicated in migraine pathophysiology, Aimovig is believed to reduce the frequency of migraine attacks.
Sources:
1. GoodRx. (n.d.). Erenumab Prices, Coupons, and Patient Assistance Programs. Retrieved from https://www.goodrx.com/erenumab
2. Aimovig. (n.d.). Savings & Support. Retrieved from https://www.aimovig.com/savings-and-support
3. Novartis Patient Assistance Foundation. (n.d.). Patient Assistance Programs. Retrieved from https://www.patientassistance.novartis.com/
4. DrugPatentWatch. (n.d.). Aimovig Patent Expirations. Retrieved from https://drugpatentwatch.com/
5. U.S. Food & Drug Administration. (n.d.). FDA Approved Drugs. Retrieved from https://www.fda.gov/drugs/development-approval-process-drugs/drug-approvals-and-database